Silo Pharma Inc., a developmental stage biopharmaceutical company, has successfully closed a public offering, raising approximately $2 million. The offering involved 3,333,338 shares of common stock, along with series A-1 and series A-2 warrants, each allowing the purchase of up to 3,333,338 additional shares at an exercise price of $0.60 per share. The Series A-1 Warrants are exercisable immediately and expire in five years, while the Series A-2 Warrants also become exercisable immediately but expire in eighteen months. The funds raised will be used for general working capital. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。